blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4048397

EP4048397 - GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THERAPEUTIC APPLICATIONS [Right-click to bookmark this link]
Former [2022/35]GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
[2023/20]
StatusNo opposition filed within time limit
Status updated on  20.06.2024
Database last updated on 10.07.2024
FormerThe patent has been granted
Status updated on  14.07.2023
FormerGrant of patent is intended
Status updated on  04.06.2023
FormerRequest for examination was made
Status updated on  29.07.2022
FormerThe international publication has been made
Status updated on  01.05.2021
Formerunknown
Status updated on  24.11.2020
Most recent event   Tooltip20.06.2024Lapse of the patent in a contracting state
New state(s): LU		published on 24.07.2024 [2024/30]
20.06.2024No opposition filed within time limitpublished on 24.07.2024 [2024/30]
Applicant(s)For all designated states
The Regents Of The University Of Michigan
Office Of Technology Transfer
1600 Huron Parkway, 2nd Floor
Ann Arbor, MI 48109-2590 / US
[2022/35]
Inventor(s)01 / LARSEN, Scott D.
13638 Cantaberry Ct.
South Lyon, MI 48178 / US
02 / SHAYMAN, James A.
322 Mulholland Avenue
Ann Arbor, MI 48103 / US
03 / HUTCHINGS, Kim
4717 Bluebird Court
Dexter, MI 48130 / US
04 / MOSS, Neil
199 Barlow Mountain Road
Ridgefield, CT 06877 / US
05 / JIANG, Qin
Utica Avenue 37
Latham, NY 12110 / US
06 / MAYHEW, Nicholas
771 Huntingdon Drive
Niskayuna, NY 12309 / US
07 / FREEMAN, Emily
24 Deer Cliff Rd.
Voorheesville, NY 12186 / US
08 / HASHEMI, Zohreh, Sajjadi
2A Norva Ave.
Frederick, MD 21701 / US
 [2022/35]
Representative(s)Schlich, George, et al
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
[2022/35]
Application number, filing date20807578.822.10.2020
[2022/35]
WO2020US56741
Priority number, dateUS201962924959P23.10.2019         Original published format: US 201962924959 P
[2022/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021081141
Date:29.04.2021
Language:EN
[2021/17]
Type: A1 Application with search report 
No.:EP4048397
Date:31.08.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 29.04.2021 takes the place of the publication of the European patent application.
[2022/35]
Type: B1 Patent specification 
No.:EP4048397
Date:16.08.2023
Language:EN
[2023/33]
Search report(s)International search report - published on:EP29.04.2021
ClassificationIPC:A61P3/10, A61P13/12, A61P25/00, A61P25/16, C07D205/04, C07D207/10, C07D295/13, A61K31/40
[2022/35]
CPC:
C07D295/13 (EP); C07D205/04 (EP,US); A61P13/12 (EP);
A61P25/00 (EP); A61P25/16 (EP); A61P3/10 (EP);
C07D207/09 (US); C07D207/10 (EP); C07D405/12 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/35]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:GLUCOSYLCERAMIDSYNTHASEHEMMER FÜR THERAPEUTISCHE ANWENDUNGEN[2023/20]
English:GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THERAPEUTIC APPLICATIONS[2023/20]
French:INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE POUR DES APPLICATIONS THÉRAPEUTIQUES[2023/20]
Former [2022/35]GLUCOSYLCERAMIDSYNTHASEHEMMER UND THERAPEUTISCHE VERFAHREN DAMIT
Former [2022/35]GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
Former [2022/35]INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
Entry into regional phase03.05.2022National basic fee paid 
03.05.2022Designation fee(s) paid 
03.05.2022Examination fee paid 
Examination procedure03.05.2022Examination requested  [2022/35]
03.05.2022Date on which the examining division has become responsible
15.06.2022Amendment by applicant (claims and/or description)
05.06.2023Communication of intention to grant the patent
06.07.2023Fee for grant paid
06.07.2023Fee for publishing/printing paid
06.07.2023Receipt of the translation of the claim(s)
Opposition(s)17.05.2024No opposition filed within time limit [2024/30]
Fees paidRenewal fee
03.05.2022Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT16.08.2023
CZ16.08.2023
DK16.08.2023
EE16.08.2023
ES16.08.2023
FI16.08.2023
HR16.08.2023
LT16.08.2023
LV16.08.2023
MC16.08.2023
NL16.08.2023
PL16.08.2023
RO16.08.2023
RS16.08.2023
SE16.08.2023
SK16.08.2023
SM16.08.2023
LU22.10.2023
NO16.11.2023
GR17.11.2023
IS16.12.2023
PT18.12.2023
[2024/30]
Former [2024/28]AT16.08.2023
CZ16.08.2023
DK16.08.2023
EE16.08.2023
ES16.08.2023
FI16.08.2023
HR16.08.2023
LT16.08.2023
LV16.08.2023
MC16.08.2023
NL16.08.2023
PL16.08.2023
RO16.08.2023
RS16.08.2023
SE16.08.2023
SK16.08.2023
SM16.08.2023
NO16.11.2023
GR17.11.2023
IS16.12.2023
PT18.12.2023
Former [2024/23]AT16.08.2023
CZ16.08.2023
DK16.08.2023
EE16.08.2023
ES16.08.2023
FI16.08.2023
HR16.08.2023
LT16.08.2023
LV16.08.2023
NL16.08.2023
PL16.08.2023
RO16.08.2023
RS16.08.2023
SE16.08.2023
SK16.08.2023
SM16.08.2023
NO16.11.2023
GR17.11.2023
IS16.12.2023
PT18.12.2023
Former [2024/22]AT16.08.2023
CZ16.08.2023
DK16.08.2023
FI16.08.2023
HR16.08.2023
LT16.08.2023
LV16.08.2023
NL16.08.2023
PL16.08.2023
RO16.08.2023
RS16.08.2023
SE16.08.2023
SM16.08.2023
NO16.11.2023
GR17.11.2023
IS16.12.2023
PT18.12.2023
Former [2024/20]AT16.08.2023
FI16.08.2023
HR16.08.2023
LT16.08.2023
LV16.08.2023
NL16.08.2023
PL16.08.2023
RS16.08.2023
SE16.08.2023
SM16.08.2023
NO16.11.2023
GR17.11.2023
IS16.12.2023
PT18.12.2023
Former [2024/10]AT16.08.2023
FI16.08.2023
HR16.08.2023
LT16.08.2023
LV16.08.2023
NL16.08.2023
PL16.08.2023
RS16.08.2023
SE16.08.2023
NO16.11.2023
GR17.11.2023
IS16.12.2023
PT18.12.2023
Former [2024/09]AT16.08.2023
FI16.08.2023
LT16.08.2023
NL16.08.2023
SE16.08.2023
NO16.11.2023
GR17.11.2023
IS16.12.2023
Former [2024/08]LT16.08.2023
NL16.08.2023
NO16.11.2023
GR17.11.2023
Cited inInternational search[A]WO2016126572  (UNIV MICHIGAN [US]) [A] 1-30 * claim 1 ** examples *
by applicantUS5302609
 US5472969
 US5525616
 US5849326
 US5916911
 US5945442
 US5952370
 US6030995
 US6051598
 US6255336
 US6569889
 US6610703
 US6660794
 US6855830
 US6916802
 US7196205
 US7253185
 WO2008150486
 WO2009117150
 US7615573
 WO2010014554
 WO2012129084
    - K.M. ASHE et al., Plos One, (20110000), vol. 6, page e21758
    - Z. MA et al., Tetrahedron: Asymmetry, (19970000), vol. 8, no. 6, pages 883 - 888
    - J.R. MAZZULLI et al., Cell, (20110708), vol. 146, pages 37 - 52
    - M. SVENSSON et al., Infect. And Immun., (19940000), vol. 62, pages 4404 - 4410
    - J. INOKUCHI et al., Cancer Lett., (19870000), vol. 38, pages 23 - 30
    - S. HAKOMORI, Cancer Cells, (19910000), vol. 3, pages 461 - 470
    - J. INOKUCHI et al., Cancer Res., (19900000), vol. 50, pages 6731 - 6737
    - M. ZICHE et al., Lab Invest., (19920000), vol. 67, pages 711 - 715
    - T.A. NATOLI et al., Nat. Med., (20100000), vol. 16, pages 788 - 792
    - N. W. BARTON et al., N Engl J Med, (19910000), vol. 324, pages 1464 - 1470
    - N.S. RADIN, Glycoconj J, (19960000), vol. 13, pages 153 - 157
    - J.A. SHAYMAN et al., Methods Enzymol, (20000000), vol. 311, pages 373 - 387
    - N.J. WEINREB et al., Am J Hematol, (20050000), vol. 80, pages 223 - 229
    - J.A. SHAYMAN, Drugs of the Future, (20100000), vol. 35, pages 613 - 621
    - E. LUKINA et al., Blood, (20100000), vol. 116, no. 20, pages 4095 - 8
    - A. ABE et al., J Clin Invest, (20000000), vol. 105, pages 1563 - 1571
    - Y. LIU et al., The Journal of clinical investigation, (19990000), vol. 103, pages 497 - 505
    - L. et al., J Biol Chem, (20030000), vol. 278, pages 31419 - 31425
    - K.M. MAHAR DOAN et al., The Journal of pharmacology and experimental therapeutics, (20020000), vol. 303, pages 1029 - 1037
    - D.S. WISHART et al., Nucleic Acids Res, (20080000), vol. 36, pages D901 - 906
    - M. LIMBO et al., J Biochem-Tokyo, (20000000), vol. 127, pages 485 - 491
    - C.A. LIPINSKI et al., Advanced Drug Delivery, (19970000), vol. 23, pages 3 - 25
    - P. GARBERG et al., Toxicol In Vitro, (20050000), vol. 19, pages 299 - 334
    - Q. WANG et al., Int J Pharm, (20050000), vol. 288, pages 349 - 359
    - P.D. LEESON et al., J Med Chem, (20040000), vol. 47, pages 6338 - 6348
    - H. PAJOUHESH et al., NeuroRx, (20050000), vol. 2, pages 541 - 553
    - R. CECCHELLI et al., Nat Rev Drug Discov, (20070000), vol. 6, pages 650 - 661
    - S. LUNDQUIST et al., Pharm Res, (20020000), vol. 19, pages 976 - 981
    - U. ANDERSSON et al., Biochemical pharmacology, (20000000), vol. 59, no. 7, pages 821 - 829
    - R.C. BAEK et al., Neurochemistry international, (20080000), vol. 52, no. 6, pages 1125 - 1133
    - R.C. BAEK et al., Lipids, (20090000), vol. 44, no. 3, pages 197 - 205
    - C.A. DENNY et al., Journal of neuroscience research, (20060000), vol. 83, no. 6, pages 1028 - 1038
    - C.A. DENNY et al., Journal of neurochemistry, (20100000), vol. 113, no. 6, pages 1525 - 1535
    - H. GALJAARD, Annals of Clinical Biochemistry, (19790000), vol. 16, no. 6, pages 343 - 353
    - T. N. SEYFRIED et al., Biochemical genetics, (19790000), vol. 17, no. 1-2, pages 241 - 257
    - M. JEYAKUMAR et al., Blood, (20010000), vol. 97, no. 1, pages 327 - 329
    - M. JEYAKUMAR et al., Neuropathology and applied neurobiology, (20020000), vol. 28, no. 5, pages 343 - 357
    - M. JEYAKUMAR et al., Brain : a journal of neurology, (20030000), vol. 126, pages 974 - 987
    - J. L. KASPERZYK et al., Journal of neurochemistry, (20040000), vol. 89, no. 3, pages 645 - 653
    - J. L. KASPERZYK et al., Journal of lipid research, (20050000), vol. 46, no. 4, pages 744 - 751
    - T. KOLTER et al., Biochimica et Biophysica Acta, (20060000), vol. 1758, no. 12, pages 2057 - 2079
    - S. KYRKANIDES et al., Journal of neuroimmunology, (20080000), vol. 203, no. 1, pages 50 - 57
    - L. J. MACALA et al., Journal of lipid research, (19830000), vol. 24, no. 9, pages 1243 - 1250
    - D. PHANEUF et al., Human molecular genetics, (19960000), vol. 5, no. 1, pages 1 - 14
    - K. SANGO et al., Nature genetics, (19950000), vol. 11, no. 2, pages 170 - 176
    - T. N. SEYFRIED et al., Biochemical genetics, (19800000), vol. 18, no. 11-12, pages 1229 - 1237
 US20050202340
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.